Coronary Artery Disease Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies

DelveInsight's, "Coronary Artery Disease Pipeline Insight" report provides comprehensive insights about 30+ companies and 25+ pipeline drugs in Coronary Artery Disease pipeline landscape. It covers the Coronary Artery Disease pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Coronary Artery Disease therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Stay ahead with the latest insights! Download DelveInsight's comprehensive Coronary Artery Disease Pipeline Report to explore emerging therapies, key Coronary Artery Disease Companies, and future Coronary Artery Disease treatment landscapes @ Coronary Artery Disease Pipeline Outlook Report [https://www.delveinsight.com/sample-request/coronary-artery-disease-cad-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Coronary Artery Disease Pipeline Report

* In February 2025:- MedTrace Pharma A/S:- This a Phase 3, prospective, open-label, multicenter study of [15-O]-H2O injection for PET imaging of subjects with suspected CAD. Approximately 182 evaluable participants with suspected CAD referred for testing will be included in the study at approximately 10 study sites in the United States and Europe. Approximately 215 participants will be enrolled to account for an estimated 15% drop-out rate.
* In February 2025:- Novartis Pharmaceuticals :- The purpose of this study is to evaluate the efficacy of inclisiran compared to placebo on top of maximally tolerated dose of statin therapy in reducing total coronary atheroma volume assessed by CCTA in participants with a diagnosis of Non-Obstructive Coronary Artery Disease (NOCAD) without previous cardiovascular events, who have an LDL-C greater than or equal to 55 mg/dL (1.4 mmol//L), no significant pressure drop in Fractional Flow Reserve Computed Tomography (FFRCT) and a CT-adapted Leaman score >5 despite the use of maximally tolerated statin therapy(and if applicable, another LLT on top of statin therapy for at least 30 days in up to 20% of randomized participants).
* In February 2025:- Beijing Inno Medicine Co., Ltd.:- This study is to evaluate the efficacy and safety of intravenously administered YN001 in patients with coronary atherosclerosis in Australia. This study will be conducted in eligible participants with a diagnosis of coronary atherosclerosis, and at least 1 coronary artery is blocked determined by coronary computed tomography angiography (CCTA)
* DelveInsight's Coronary Artery Disease pipeline report depicts a robust space with 30+ active players working to develop 25+ pipeline therapies for Coronary Artery Disease treatment.
* The leading Coronary Artery Disease Companies such as Novartis Pharmaceuticals, Amgen, Imbria Pharmaceuticals, Inc., AstraZeneca, Jiangsu Vcare Pharmatech, GE Healthcare , and others.
* Promising Coronary Artery Disease Therapies such as Rosuvastatin, Atorvastatin, Hexadecasaccharide (SR123781A), Rosuvastatin, Rimonabant (SR141716), Rosuvastatin calcium , and others.

Discover how the Coronary Artery Disease treatment paradigm is evolving. Access DelveInsight's in-depth Coronary Artery Disease Pipeline Analysis for a closer look at promising breakthroughs @ Coronary Artery Disease Clinical Trials and Studies [https://www.delveinsight.com/sample-request/coronary-artery-disease-cad-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Coronary Artery Disease Emerging Drugs

* Flurpiridaz F-18: GE Healthcare

Flurpiridaz F-18, a fluorine 18-labeled agent was developed by Lantheus Medical Imaging for the diagnosis of coronary artery disease (CAD), the most common form of heart disease. Flurpiridaz F 18 is an investigational positron emission tomography (PET) myocardial perfusion imaging (MPI) agent. GE Healthcare has launched a second Phase III clinical trial for the use of Flurpiridaz 18F Injection in PET myocardial perfusion imaging (MPI) to detect CAD. Currently, it is in Phase III stage of clinical trial evaluation to treat Coronary Artery Disease.

* Evolocumab: Amgen

Evolocumab injection is used to reduce the risk of a stroke or heart attack or the need for coronary artery bypass (CABG) surgery in people with cardiovascular disease. Evolocumab injection is also used along with diet alone or in combination with other cholesterol-lowering medications such as HMG-CoA reductase inhibitors (statins) or ezetimbe (Zetia) to decrease the amount of low-density lipoprotein (LDL) cholesterol ('bad cholesterol') in the blood, including people who have familial heterozygous hypercholesterolemia. It is also used along with diet changes and other treatments to reduce the amount low-density lipoprotein (LDL) cholesterol in the blood in people that have homozygous familial hypercholesterolemia. It is in a class of medications called proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitor monoclonal antibody. It works by blocking the production of LDL cholesterol in the body to decrease the amount of cholesterol that may build up on the walls of the arteries and block blood flow to the heart, brain, and other parts of the body. Currently, it is in Phase III stage of clinical trial evaluation to treat Coronary Artery Disease.

* Revacept: advanceCor

Revacept seals the lesion in a blood vessel like a plaster. It acts locally at the ruptured plaque instead of involving the complete organism, as is the case for all established drugs. Revacept has proven to be very effective in laboratory tests with platelets and in animal experiments. In a Phase I clinical trial with volunteers, it was shown to be very well tolerated at all dosages. It induced a specific and dose-dependent inhibition of aggregation (clumping of platelets) in the blood of the volunteers without any relevant side effects. In particular, general haemostasis was not affected: The bleeding time was not prolonged by Revacept and there were no bleeding complications and no reduction in platelet count (thrombopenia). Currently, it is in Phase II stage of clinical trial evaluation to treat Coronary Artery Disease.

The Coronary Artery Disease pipeline report provides insights into

* The report provides detailed insights about companies that are developing therapies for the treatment of Coronary Artery Disease with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Coronary Artery Disease Treatment.
* Coronary Artery Disease Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Coronary Artery Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Coronary Artery Disease market.

Get a detailed analysis of the latest innovations in the Coronary Artery Disease pipeline. Explore DelveInsight's expert-driven report today! @ Coronary Artery Disease Unmet Needs [https://www.delveinsight.com/sample-request/coronary-artery-disease-cad-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Coronary Artery Disease Companies

Novartis Pharmaceuticals, Amgen, Imbria Pharmaceuticals, Inc., AstraZeneca, Jiangsu Vcare Pharmatech, GE Healthcare, and others.

Coronary Artery Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

* Oral
* Parenteral
* Intravenous
* Subcutaneous
* Topical

Coronary Artery Disease Products have been categorized under various Molecule types such as

* Monoclonal Antibody
* Peptides
* Polymer
* Small molecule
* Gene therapy

Download DelveInsight's latest report to gain strategic insights into upcoming Coronary Artery Disease Therapies and key Coronary Artery Disease Developments @ Coronary Artery Disease Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/coronary-artery-disease-cad-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Coronary Artery Disease Pipeline Report

* Coverage- Global
* Coronary Artery Disease Companies- Novartis Pharmaceuticals, Amgen, Imbria Pharmaceuticals, Inc., AstraZeneca, Jiangsu Vcare Pharmatech, GE Healthcare , and others.
* Coronary Artery Disease Therapies- Rosuvastatin, Atorvastatin, Hexadecasaccharide (SR123781A), Rosuvastatin, Rimonabant (SR141716), Rosuvastatin calcium , and others.
* Coronary Artery Disease Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Coronary Artery Disease Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Which companies are leading the race in Coronary Artery Disease drug development? Find out in DelveInsight's exclusive Coronary Artery Disease Pipeline Report-access it now! @ Coronary Artery Disease Emerging Drugs and Major Companies [https://www.delveinsight.com/sample-request/coronary-artery-disease-cad-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Content

* Introduction
* Executive Summary
* Coronary Artery Disease: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Coronary Artery Disease - DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Evolocumab: Amgen
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* Ninerafaxstat: Imbria Pharmaceuticals, Inc.
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* Drug profiles in the detailed report.....
* Inactive Products
* Coronary Artery Disease Key Companies
* Coronary Artery Disease Key Products
* Coronary Artery Disease- Unmet Needs
* Coronary Artery Disease- Market Drivers and Barriers
* Coronary Artery Disease- Future Perspectives and Conclusion
* Coronary Artery Disease Analyst Views
* Coronary Artery Disease Key Companies
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=coronary-artery-disease-clinical-trials-and-studies-ema-pdma-fda-approvals-mechanism-of-action-roa-nda-ind-and-companies]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/functional-dyspepsia-pipeline-insight

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.